KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Return on Equity (2016 - 2025)

Historic Return on Equity for Novavax (NVAX) over the last 15 years, with Q3 2025 value amounting to 5.74%.

  • Novavax's Return on Equity fell 63400.0% to 5.74% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.74%, marking a year-over-year decrease of 63400.0%. This contributed to the annual value of 0.28% for FY2024, which is 5300.0% down from last year.
  • Per Novavax's latest filing, its Return on Equity stood at 5.74% for Q3 2025, which was down 63400.0% from 22.24% recorded in Q2 2025.
  • In the past 5 years, Novavax's Return on Equity ranged from a high of 9.2% in Q1 2022 and a low of 31.8% during Q4 2021
  • Over the past 5 years, Novavax's median Return on Equity value was 0.5% (recorded in 2024), while the average stood at 1.98%.
  • Its Return on Equity has fluctuated over the past 5 years, first crashed by -306600bps in 2021, then surged by 329000bps in 2022.
  • Novavax's Return on Equity (Quarter) stood at 31.8% in 2021, then surged by 103bps to 1.1% in 2022, then decreased by -29bps to 0.78% in 2023, then tumbled by -58bps to 0.33% in 2024, then plummeted by -1861bps to 5.74% in 2025.
  • Its last three reported values are 5.74% in Q3 2025, 22.24% for Q2 2025, and 1.37% during Q1 2025.